## Economic Impact of Biopharmaceutical Infrastructure Investment and Union Jobs

A new PILMA study looks at America's union workforce and biopharmaceutical industry investment into building and maintaining manufacturing facilities and R&D laboratories across 18 states.

Growing America's infrastructure to make next-generation medicines supports the economic security of union construction workers in the building trades, their families and communities.

But far beyond the direct benefits to workers, including good wages and health and retirement benefits, the impact of infrastructure investment and union jobs and wages extends to the communities where workers live.

This is known as the multiplier effect.



## Overall impact of biopharmaceutical infrastructure investment and union construction jobs across 18 states

Investing in the American Economy.



\$86.5B

invested in R&D and manufacturing infrastructure (2019 – 2024)



1.048

construction projects at

703

distinct facilities



\$224B

total economic impact

Strengthening the American Workforce.



\$2.6B

skilled union wages\*

\*Not including the millions for health insurance and pension contributions



Additionally...

\$19M

in support and funding for union apprenticeships



Pro-innovation policies are critical to maintaining these investments, union jobs and income, and supporting access to transformative medicines for American patients. Don't let misguided policies close this highway to economic security for middle-class, blue-collar workers and their families.



## Sources:

- · An Analysis of Construction Spending in the Pharmaceutical & Biotech Industry, 2019-2024. Study includes 18 states.
- The Use of Economic Impact Multipliers to Assess Employment, Economic Activity, and Policy Implications of New Investments in Biopharmaceutical Industry Facilities

